← Peptides

cosmetic-topical

Matrixyl

Not FDA approved Palmitoyl Pentapeptide-4 · Pal-KTTKS · Palmitoyl Pentapeptide-3

Matrixyl (Palmitoyl Pentapeptide-4) is regulated as a cosmetic ingredient by the FDA, not as a drug. It does not require FDA approval for use in topical skincare products.

What is Matrixyl?

Matrixyl is the trade name for Palmitoyl Pentapeptide-4 (Pal-KTTKS), a synthetic lipopeptide composed of a palmitoyl fatty acid chain attached to the amino acid sequence Lys-Thr-Thr-Lys-Ser (KTTKS). This sequence is a fragment of the pro-collagen I chain. The palmitoyl group improves skin penetration through the stratum corneum.

Important: Matrixyl is a cosmetic ingredient, not a pharmaceutical. The information on this page is offered for educational and cosmetic formulation reference purposes. It is not medical advice.

Proposed mechanism of action

The KTTKS fragment signals dermal fibroblasts through matrikine pathways — small peptide fragments derived from extracellular matrix proteins that communicate tissue remodeling needs. In cell-culture models, Pal-KTTKS has been shown to upregulate the synthesis of:

  • Type I collagen (structural integrity, volume)
  • Fibronectin (adhesion, wound signaling)
  • Hyaluronic acid (hydration, matrix filling)

This “messenger” mechanism distinguishes it from simple moisturizers: rather than filling or coating, it aims to trigger the cell’s own synthesis machinery.

What the research says

A double-blind, split-face clinical study (Robinson et al., 2005) with 93 participants reported statistically significant improvements in wrinkle depth and surface roughness versus placebo after 12 weeks at 4 ppm. The study was conducted by Procter & Gamble (developer of Matrixyl) and later reproduced by independent labs at consistent results.

Multiple in-vitro studies confirm upregulation of collagen precursors at nanomolar concentrations. Comparative in-vitro work has suggested Matrixyl 3000 (a combination with Palmitoyl Tripeptide-1) may produce superior collagen stimulation versus Pal-KTTKS alone.

Typical use in formulations

  • Concentration range: 0.005–0.01% (i.e., 0.5–10 ppm by weight). Effective at sub-percent levels.
  • Optimal pH: 4.0–7.0; stable across most serum and emulsion pH ranges
  • Solubility: Partially lipophilic due to palmitoyl group; typically supplied as an aqueous solution (Sederma’s commercial Matrixyl is pre-dissolved)
  • Target area: Full-face anti-aging, fine lines and firmness loss primarily in periorbital and nasolabial regions
  • Incompatibilities: High oxidative environments may affect the peptide bond. Avoid formulating with strong oxidants (high-concentration ascorbic acid, benzoyl peroxide) without stability testing.
  • Synergies: Frequently paired with Matrixyl 3000 (Pal-GHK + Pal-KTTKS) or Argireline for complementary collagen-synthesis and expression-line coverage.

Cosmetic vs. pharmaceutical context

All claims for Matrixyl in finished products must remain within the cosmetic framework. Acceptable: “helps reduce the appearance of fine lines” or “supports skin firmness.” Not acceptable: “rebuilds collagen” or “treats wrinkles.” The ingredient acts on appearance through biological plausibility, but the regulatory distinction between cosmetic action and drug action is clear.

Reported protocol (research reference)

Reported dose Typically used at 0.5–4 ppm (parts per million) or 0.005–0.01% in finished formulations. Effective at very low concentrations relative to most cosmetic actives.
FDA status Not FDA approved
Sources: Robinson et al. — Palmitoyl Pentapeptide-4 and collagen synthesis (2005) ·Katayama et al. — KTTKS peptide extracellular matrix (1993)
This information is for educational and research reference only. It is not medical advice. We do not sell, prescribe, or recommend any treatment. Dosages cited come from research literature and are not an indication for human use. Always consult a licensed healthcare provider.